Chief Executive Officer and Managing Director, Percheron Therapeutics
| Role | Organisation | Sources |
|---|---|---|
| Chief Executive Officer and Managing Director | Percheron Therapeutics | Biotech Dispatch |
| Director | Percheron Therapeutics | Biotech Dispatch |
Stories naming Dr Michael Baker. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Melbourne biotech Percheron Therapeutics has locked in $2.3 million through an institutional placement to fund a Vanderbilt Health trial of its HMBD-002 antibody in blood cancers.
Percheron Therapeutics has appointed Arovella Therapeutics' former leader Michael Baker as CEO from October, with James Garner departing for an overseas role while joining the board as a non-executive director.